Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Date publication

juin 2017

Journal

JAMA

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FAIVRE Laurence

Tous les auteurs :
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, ,McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28632866

Résumé

The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates.

Mots clés

Adult, Age Distribution, Age Factors, Aged, Aged, 80 and over, Breast Neoplasms, epidemiology, Family, Female, Genes, BRCA1, Genes, BRCA2, Humans, Incidence, Middle Aged, Mutation, Neoplasms, Second Primary, epidemiology, Ovarian Neoplasms, epidemiology, Prospective Studies, Risk Assessment, Time Factors

Référence

JAMA. 2017 06 20;317(23):2402-2416